Form 4: Ramaswamy Exercises, Sells Roivant Shares

Vivek Ramaswamy, a 10% owner and director of Roivant Sciences Ltd., exercised stock options and subsequently sold a portion of the acquired shares, while also using net settlement for others, across multiple transactions in December 2025.

Summary

• Vivek Ramaswamy, a Director and 10% owner of Roivant Sciences Ltd. (ROIV), engaged in a series of transactions involving the exercise of stock options and the subsequent sale or net settlement of common shares.
• Between December 11 and December 15, 2025, Ramaswamy exercised a total of 7,374,868 stock options at an exercise price of $12.68 per share.
• Concurrently, he disposed of 3,103,745 common shares through open market sales at weighted average prices ranging from $21.64 to $22.05.
• An additional 4,271,124 common shares were disposed of through "net settlement" with the Issuer to cover the exercise price applicable to the options.
• Following these transactions, Ramaswamy directly holds 33,653,755 common shares and indirectly holds 13,357,857 common shares through spousal ownership.
• The exercised options were set to expire in March 2026 and had a vesting commencement date of December 27, 2019.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a significant insider realized substantial gains from exercising options and selling shares at a higher market price. While it represents a reduction in direct holdings, it's a common and expected action for monetizing equity compensation, especially for options nearing expiration. The insider retains a very substantial direct and indirect stake.

Positives

• Ramaswamy realized significant value by exercising options at $12.68 and selling shares at weighted average prices between $21.64 and $22.05, indicating a substantial profit margin on the exercised shares.
• The transactions demonstrate the monetization of long-held equity incentives, with options vesting since December 2019.

Negatives

• The sale of a significant number of shares by a 10% owner and director could be perceived as a reduction in direct exposure to the company's future performance, although a substantial direct and indirect holding remains.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Vivek Ramaswamy, a Director and 10% owner, engaged in transactions involving the exercise of stock options and the sale/net settlement of shares with the issuer, which are considered related party transactions due to his significant role and ownership.

Stakeholder Impact

• Shareholders: The sale of shares by a significant insider could be interpreted differently by investors; some might see it as a lack of confidence, while others might view it as a routine monetization of equity compensation. The remaining substantial holding might reassure investors.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

While a significant insider has monetized a portion of their equity, this appears to be a routine exercise of expiring options and subsequent sales to realize gains and cover costs. The insider retains a very substantial direct and indirect ownership stake, suggesting continued alignment with the company's performance. The transactions do not indicate a fundamental shift in the company's prospects, but rather a personal financial decision. Investors should monitor future insider activity and company performance, but this specific filing does not warrant a change from a 'hold' position.

Keywords

Roivant Sciences, ROIV, Vivek Ramaswamy, Insider Trading, Form 4, Stock Options, Share Sale, Beneficial Ownership, Equity Compensation, Director Transactions, 10% Owner